Qingsong Health joins the China Pharmaceutical Industry Chamber of Commerce as an executive council member.

Qingsong Health Group has officially become an executive council member of the China Pharmaceutical Industry Chamber of Commerce under the All-China Federation of Industry and Commerce. Joining this national pharmaceutical industry organization and serving as an executive council member reflects further recognition of Qingsong Health's comprehensive capabilities in pharmaceutical and health services, digital capability building, medical AI innovation and industry ecosystem collaboration.

The China Pharmaceutical Industry Chamber of Commerce is a chamber directly affiliated with the All-China Federation of Industry and Commerce and a national-level social organization. It serves as an important bridge between the Party, the government and the pharmaceutical industry. The chamber has long supported pharmaceutical companies, promoted industry exchange and advanced reform, innovation and high-quality development in the pharmaceutical sector. As an executive council member, Qingsong Health will take part more deeply in the chamber's work and work with upstream and downstream companies, medical institutions, research organizations and industry partners to explore new paths for digital and intelligent development in healthcare.

As a representative company in China's digital health sector, Qingsong Health has long focused on pharmaceutical and health services. Around user health management, pharmaceutical enterprise services, early screening services, medical content and medical AI, it has built an integrated health service ecosystem connecting users, doctors, pharmaceutical companies, insurers and medical institutions. According to the company's 2025 results, Qingsong Health generated about RMB 1.256 billion in annual revenue, up 32.9% year over year. Health-related service revenue reached RMB 926 million and accounted for 73.7% of total revenue, becoming the company's core growth engine.

For pharmaceutical industry services, Qingsong Health relies on its accumulated user base, health content capabilities, digital operation system and medical service network to provide pharmaceutical companies with digital marketing, disease education, early screening promotion, patient management and medical research support. These services help pharmaceutical partners reach target populations more efficiently, improve disease awareness and complete patient service workflows. By the end of 2025, Qingsong Health's platform had more than 168.6 million registered users, 63.8 million followers across channels and partnerships with 103 pharmaceutical companies, representing a 66.1% increase in pharmaceutical partners from the end of the previous year.

As artificial intelligence plus healthcare moves into accelerated implementation, Qingsong Health has continued to embed AI capabilities throughout pharmaceutical and health service workflows, supporting the shift from a connection-based platform to an intelligent platform. Based on its self-developed AIcare technology stack and medical AI product capabilities, the company continues to explore health content production, user segmentation, disease risk identification, medical information processing and clinical decision support. It has also launched QSevidence, an evidence-based medical agent that uses explainable, verifiable and traceable evidence-based medicine methodology to provide doctors and medical professionals with more rigorous decision support.

Becoming an executive council member is both an honor and a responsibility. Qingsong Health will draw on its strengths in user scale, pharmaceutical partnerships, digital health services and medical AI productization to fulfill its role, participate deeply in industry exchange and collaboration, and continue to contribute technology and platform experience in pharmaceutical innovation services, full-course patient management, medical science communication, disease early screening and evidence-based medical AI.

The pharmaceutical and health industry is at a critical stage of digital transformation and intelligent upgrading. Starting from this new role, Qingsong Health will strengthen cooperation with the chamber and its member companies, promote deeper integration of AI technology with real healthcare scenarios, help the industry improve service efficiency, expand service boundaries and complete health management loops, and contribute more digital and intelligent capabilities to high-quality development of China's pharmaceutical and health industry.

Original source: https://www.qingsonghealth.com/show-92.html